头孢曲松与头孢噻肟治疗下呼吸道感染成本效果分析  

A Cost-effectiveness Analysis of Ceftriazone and Cefotaxime in Treatment of Lower Respiratory Tract Infections

作　　者：温预关[1] 石红梅[1] 王丽霞[1] 

机构地区：[1]广州市精神病医院,510370

出　　处：《医药导报》2001年第11期726-727,共2页Herald of Medicine

摘　　要：目的 :探讨头孢曲松与头孢噻肟治疗轻中度下呼吸道感染的经济效果。方法 :将 2 0 0例患者随机分为两组 ,A组 (头孢曲松 ) 10 3例 ,B组 (头孢噻肟 ) 97例 ,用药物经济学方法进行成本 效果分析。结果 :A ,B组治疗方案的痊愈率分别为 38.8% ,2 4.7% ,有效率分别为 80 .6 % ,6 5 .0 % ,A组的成本 效果比在治疗三种下呼吸道感染中均低于B组。结论 :头孢曲松治疗轻中度下呼吸道感染优于头孢噻肟 。Objective:To evaluate the cost effectiveness and safety of ceftriazone and cefotaxime in treatment of mild to moderate lower respiratory tract infections. Methods:Two hundred patients with mild to moderate respiratory tract infections were randomly divided into two groups, treated by use of ceftriazone and cefotaxime, respectively. Cost effectiveness analysis was conducted with pharmaco economic method. Results: The curative and effective rates in those treated with cefriazone and cefotaxime were 38.83% versus 24.74% and 80.58% versus 64.95% in the treatment of three kinds of mild to moderate lower respiratory tract infections. Conclusion:Ceftriazone is better than cefotaxime in the treatment of mild to moderate lower respiratory tract infections, and is a cost effective and safe drug.

关 键 词：头孢曲松 头孢噻肟 下呼吸道感染 成本-效果分析 药物经济学 

分 类 号：R978.11[医药卫生—药品] R56[医药卫生—药学]